FDA removes semaglutide from drug shortage list
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk announced.On Feb. 21, the FDA updated its drug shortage list and listed the shortage of all doses of injectable semaglutide (Ozempic/Wegovy) as being resolved.
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.
Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows
A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday. The resol
Hims & Hers Health Shares Tumble After Novo Nordisk Says Wegovy, Ozempic Shortage is Over
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
US FDA Says Shortage of Novo's Weight-Loss Drug Resolved
All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October, but the treatments were not taken off the offi
Novo’s Ozempic, Wegovy Shortage Ends, Threatening Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.
FDA to spare compounders as Novo Nordisk’s Ozempic supply begins to improve
The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs as supply conditions for the GLP-1s improve after an official end to their shortage.
Medpage Today on MSN1d
Semaglutide Tied to Small Risk of Potentially Blinding Eye Condition
The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
FiercePharma1h
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has ...
Beyond Weight Loss: Semaglutide Could Curb Alcohol Cravings According to USC Study
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Healio23h
Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes
Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...
Semaglutide Side Effects: Is It Safe? What You Need To Know
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
ABC News on MSN8d
Weight loss drug semaglutide may reduce alcohol cravings, heavy drinking and smoking, new study finds
Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...
News Medical11d
What's Next for Semaglutide? Beyond Diabetes and Weight Loss
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
People’s Pharmacy: One more reason to try to lose extra weight
A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of hospitalization from heart failure and deaths from cardiovascular causes ...